Metastatic Castration-Resistant Prostate Cancer Trials in South Korea, 2026
Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.
About this register
This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,401 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.
This page shows the 11 of those studies listing the condition Metastatic Castration-Resistant Prostate Cancer.
How many Metastatic Castration-Resistant Prostate Cancer trials are recruiting in South Korea?
8 of the 11 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.
Summary by phase
| Phase | Studies | Recruiting | Share |
|---|---|---|---|
| Phase 3 | 6 | 3 | 54.5% |
| Phase 2 | 3 | 3 | 27.3% |
| Observational | 1 | 1 | 9.1% |
| Phase 1 | 1 | 1 | 9.1% |
Most active sponsors
| Lead sponsor | Studies | Recruiting |
|---|---|---|
| AstraZeneca | 3 | 2 |
| Amgen | 2 | 1 |
| Astellas Pharma Global Development, Inc. | 1 | 1 |
| Celgene | 1 | 0 |
| Hoffmann-La Roche | 1 | 1 |
| IntoCell, Inc | 1 | 1 |
| Novartis Pharmaceuticals | 1 | 1 |
| Pfizer | 1 | 1 |